RE:RE:RE:RE:RE:Our first hit piece... we made it!Well, he did do quite a bit of reserach and brought in the opinion views of two other scientists so I'm not sure I'd call it just his 'opinion'. He also seems to have more of a background (Masters in molecular biology) than probably most shareholders, including myself, so he's got a bit more weight to his points of view.
Of course, he may be wrong, but just making a judgement call here. It wasn't a matter of patience (I own many shares of QRTH just to back that up!) and I'm not prone to make rash/quick decisions like this but there really isn't all that much scientific reserach to back Biocloud up at the moment.
Chi